{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:46:23Z","timestamp":1792039583628,"version":"4.4.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.farma.2026.09.002","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:06:08Z","timestamp":1792037168000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world adherence to biologic therapies targeting interleukin 17, interleukin 23 and ustekinumab in moderate-to-severe psoriasis: A multicenter cohort study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-3910","authenticated-orcid":false,"given":"Mar\u00eda","family":"Calvo-Arbeloa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n San","family":"Miguel-Elcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaya","family":"Arrondo-Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2375-0053","authenticated-orcid":false,"given":"Maite","family":"Sarobe-Carricas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0248-4208","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Borr\u00e1s-Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.farma.2026.09.002_bb0005","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis severity, comorbidities, and treatment patterns in the United States: Results from a population-based study","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.farma.2026.09.002_bb0010","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology life quality index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.farma.2026.09.002_bb0015","series-title":"Adherence to long-term therapies: evidence for action","author":"World Health Organization","year":"2003"},{"issue":"4","key":"10.1016\/j.farma.2026.09.002_bb0020","first-page":"504","article-title":"Medication adherence measures: an overview","volume":"79","author":"Lam","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.farma.2026.09.002_bb0025","doi-asserted-by":"crossref","DOI":"10.1093\/intqhc\/mzae026","article-title":"Integration of persistence in the 5P-medicine approach for age-related chronic diseases","volume":"36","author":"Borr\u00e1s-Blasco","year":"2024","journal-title":"Int J Qual Health Care"},{"issue":"5","key":"10.1016\/j.farma.2026.09.002_bb0030","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1177\/10600280251363950","article-title":"Persistence within 6P medicine model has value for clinical decision only when adherence is assessed","volume":"60","author":"Borr\u00e1s-Blasco","year":"2025","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.farma.2026.09.002_bb0035","first-page":"56","article-title":"Adherence to treatment with adalimumab, golimumab and ustekinumab in patients with inflammatory bowel disease","volume":"44","author":"Calvo-Arbeloa","year":"2020","journal-title":"Farm Hosp"},{"issue":"9","key":"10.1016\/j.farma.2026.09.002_bb0040","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1185\/03007990903126833","article-title":"Good and poor adherence: optimal cut-point for adherence measures using administrative claims data","volume":"25","author":"Karve","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.farma.2026.09.002_bb0045","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.farma.2026.09.002_bb0050","first-page":"191","article-title":"Drug utilization and medication adherence for the treatment of psoriatic arthritis: an Italian study","volume":"11","author":"Santoleri","year":"2024","journal-title":"Glob Reg Health Technol Assess"},{"issue":"6","key":"10.1016\/j.farma.2026.09.002_bb0055","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3390\/jcm11061506","article-title":"Adherence and persistence to biological drugs for psoriasis: systematic review with meta-analysis","volume":"11","author":"Piragine","year":"2022","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.farma.2026.09.002_bb0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/09546634.2018.1479725","article-title":"Treatment patterns, adherence and persistence among psoriasis patients treated with biologics in real-world setting, overall and by disease severity","volume":"30","author":"Murage","year":"2019","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.farma.2026.09.002_bb0065","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bjd.12648","article-title":"Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis","volume":"170","author":"Van den Reek","year":"2014","journal-title":"Br J Dermatol"},{"issue":"10198","key":"10.1016\/j.farma.2026.09.002_bb0070","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in moderate-to-severe plaque psoriasis (IMMvent)","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.farma.2026.09.002_bb0075","first-page":"1357","article-title":"Long-term efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis","volume":"35","author":"Warren","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.farma.2026.09.002_bb0080","article-title":"Biologic treatment patterns and outcomes in moderate-to-severe psoriasis in clinical practice","volume":"32","author":"Puig","year":"2019","journal-title":"Dermatol Ther"},{"issue":"10091","key":"10.1016\/j.farma.2026.09.002_bb0085","first-page":"228","article-title":"Efficacy and safety of guselkumab compared with adalimumab for moderate-to-severe psoriasis (VOYAGE 1 and 2)","volume":"390","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.farma.2026.09.002_bb0090","first-page":"839","article-title":"Efficacy and safety of guselkumab through 100 weeks in moderate-to-severe psoriasis","volume":"182","author":"Gordon","year":"2020","journal-title":"Br J Dermatol"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326002199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634326002199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:06:11Z","timestamp":1792037171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634326002199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":18,"alternative-id":["S1130634326002199"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2026.09.002","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world adherence to biologic therapies targeting interleukin 17, interleukin 23 and ustekinumab in moderate-to-severe psoriasis: A multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2026.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}